Kura Oncology's (KURA) ziftomenib shows AML promise amid competition. See why I'm inclined to view the current price levels ...

With this circuit, CEA-Leti demonstrated 4- and 16-point QAM, that increases the possible number of multiplexed devices by ...

Microsoft, Amazon, and Google each announced new prototypes of quantum computing chips, but scientists say that the field is ...

Spyre Therapeutics' innovative combination therapy approach targets multiple inflammatory pathways. Learn why SYRE stock is a Buy.

Alumis Inc. (Nasdaq: ALMS) (“Alumis”) and ACELYRIN, INC. (Nasdaq: SLRN) (“ACELYRIN”) today reaffirmed their commitment to merge in an all-stock transaction, which will create a leading clinical stage ...

Q4 2024 Earnings Call Transcript March 3, 2025 Ocular Therapeutix, Inc. misses on earnings expectations. Reported EPS is ...

News archive including articles on Fund Managers, Fund Selection, Asset Allocation, Absolute Return, Offshore Investments, Tax Shelters, Insurance bonds. Five years after Covid, the biotech investment ...

FORWARD-53 is an ongoing Phase 2 open-label trial of WVE-N531. Muscle biopsies are taken after 24 and 48 weeks of dosing. The ...

With a pro forma cash position of approximately $737 million as of December 31, 2024, and continued operating discipline, Alumis expects that this cash position provides runway to advance the combined ...

Striking study results last year indicated a new type of medicine may improve on Merck’s dominant immunotherapy, spurring a ...

Repare Therapeutics Inc ( ($RPTX) ) has released its Q4 earnings. Here is a breakdown of the information Repare Therapeutics Inc presented to its ...